May 8, 2024 03:58 AM EDTUpdated 06:28 AM
R&D
Pharma
Coronavirus

As­traZeneca pulls Covid-19 vac­cine glob­al­ly as the phar­ma sees 'no fu­ture com­mer­cial de­mand'

Kyle LaHucik

Senior Reporter

As­traZeneca is with­draw­ing its Ox­ford-col­lab­o­rat­ed Covid-19 vac­cine from glob­al mar­kets, the UK-based phar­ma com­pa­ny con­firmed in a state­ment to End­points News on Tues­day.

The spokesper­son …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times